Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies in Healthcare Personnel in El Salvador Prior to Vaccination CampaignsArticle Published on 2024-06-072024-09-05 Journal: Infectious Disease Reports [Category] update2024, [키워드] COVID-19 El Salvador SARS-CoV-2 Seroprevalence Spike protein [DOI] 10.3390/idr16030040 PMC 바로가기 [Article Type] Article
Perinatal dengue and Zika virus cross-sectional seroprevalence and maternal-fetal outcomes among El Salvadoran women presenting for labor-and-deliveryResearch Published on 2024-04-022024-09-05 Journal: Maternal Health, Neonatology and Perinatology [Category] update2024, [키워드] dengue virus El Salvador flavivirus Health disparities health outcomes maternal-fetal medicine parturition Zika virus [DOI] 10.1186/s40748-024-00177-5 PMC 바로가기 [Article Type] Research
Identifying opportunities to engage communities with social mobilisation activities to tackle NCDs in El Salvador in the context of the global COVID-19 pandemicResearch Published on 2021-10-092022-10-29 Journal: International journal for equity in health [Category] Coronavirus, MERS, SARS, [키워드] activities activity addressed benefit Combination Community conducted COVID-19 COVID-19 pandemic effective El Salvador engage Facebook Factor finding form formative Fragile settings Gender Government Health health team identifying implication include increasingly interview less management mechanism men New Non-communicable disease non-communicable diseases Patient platform professional Result seeking Social mobilisation Structure Support Treatment WhatsApp with COVID-19 women [DOI] 10.1186/s12939-021-01559-3 PMC 바로가기 [Article Type] Research
Disproportionality analysis of reported drug adverse events to assess a potential safety signal for pentavalent vaccine in 2019 in El Salvador2019년 엘살바도르에서 오가나 백신의 잠재적 안전 신호를 평가하기 위한 보고된 약물 부작용 사건의 불균형 분석Article Published on 2021-08-092024-08-18 Journal: Vaccine [Category] 백일해, 파상풍, [키워드] Adverse events following immunization El Salvador febrile seizure pentavalent vaccine pharmacovigilance vaccine safety [DOI] 10.1016/j.vaccine.2021.07.010